In Vitro Activities of CG400549, a Novel FabI Inhibitor, against Recently Isolated Clinical Staphylococcal Strains in Korea

The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC(90) of 0.5 μg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.

Guardat en:
Dades bibliogràfiques
Autors principals: Yum, Jong Hwa, Kim, Chang Ki, Yong, Dongeun, Lee, Kyungwon, Chong, Yunsop, Kim, Cheol Min, Kim, Jeong Mi, Ro, Seonggu, Cho, Joong Myung
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology (ASM) 2007
Matèries:
Susceptibility
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1913239/
https://ncbi.nlm.nih.gov/pubmed/17420210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01562-06
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars